The average body weight increase due to glibenclamide therapy at the end of 3 years was 4.8 kg (from UKPDS). It was reported from a study that "acarbose treatment is body weight-neutral". From the DIS patient sample (1,139), a total of 316 patients who had regular quarterly follow-up visits, and who experienced either stablebody weight change (less than or equal to 2 kg) or increased body weight (greater than 2 kg) were selected for the economic analysis. Since the mean body weight increase in the increased group was 4.78 kg (SD=2.03 kg), it was decided that the stable group (group A, with 185 patients), and the increased group (group B, with 131 subjects) could represent patients having acarbose therapy and glibenclamide therapy, respectively. The probabilities attributed to the pathways of patients with ECG without pathological findings were as follows: patients with angina pectoris (AP), 0.25; patients with AP who end up with percutaneous transluminal coronary angioplasty (PTCA), 0.2, with coronary artery bypass graft (CABG), 0.1, or with conservative drug therapy, 0.7;CABGpatients who end up with institutional rehabilitation, 0.85.
The probabilities attributed to the pathways of patients with ischaemic ECG abnormalities were as follows:
patients with AP, 0.5;
patients with AP who end up with PTCA, 0.55,
patients with AP who end up with CABG, 0.3,
patients with AP who end up with conservative drug therapy, 0.15;
CABGpatients who end up with institutional rehabilitation, 0.85;
patients without AP, 0.5;
patients without AP who end up with PTCA, 0.1;
patients without AP who end up with CABG, 0.05,
patients without AP who end up with conservative drug therapy, 0.85;
CABGpatients who end up with institutional rehabilitation, 0.85.
The probabilities attributed to the pathways of patients with ECG signs of silent myocardial infarction (MI) were as follows:
patients with AP, 0.25;
patients with AP who end up with PTCA, 0.4,
patients with AP who end up with CABG, 0.4,
patients with AP who end up with conservative drug therapy, 0.2;
CABG patients who end up with institutional rehabilitation, 0.85;
patients without AP, 0.75;
patients without AP who end up with PTCA, 0.1,
patients without AP who end up with CABG, 0.05,
patients without AP who end up with conservative drug therapy, 0.85;
CABGpatients who end up with institutional rehabilitation, 0.85.
The probabilities attributed to the pathways of patients with clinical MI were as follows:
patients with PTCA, 0.3,
patients with CABG, 0.05,
patients with conservative drug therapy, 0.65;
CABG or PTCA patients who end up with institutional rehabilitation (IR), 0.85,
IR or without IR patients without AP, 0.75;
patients with conservative drug therapy who end up with IR, 0.85,
IR or without IR patients without AP, 0.75,
without IR patients without AP who end up withPICA, 0.1,
without IR patients without AP who end up with CABG, 0.05,
without IR patients without AP who end up with conservative drug therapy, 0.85,
CABGpatients who end up with institutional rehabilitation, 0.85;
patients with conservative drug therapy with IR or without IR who end up with AP, 0.25,
AP patients who end up with PTCA, 0.4,
AP patients who end up with CABG, 0.4,
AP patients who end up with conservative drug therapy, 0.2;
CABGpatients who end up with institutional rehabilitation, 0.85.